Renhuang Pharmaceuticals, Inc (RHGP.OB) has been rated ‘Outperform’ with a price target of $7.00 by Beacon Equity Research. Renhuang Pharmaceutical is a company focused on developing, manufacturing, and distributing high quality natural medicine and bio-pharmaceutical products in China. Currently, the company offers three main product lines: Acanthopanax-based natural medicinal products, the Shark Power healthcare series, and Traditional Chinese Medicines. Sales for each product represent 50%, 20% and 30%, respectively.
Renhuang has also established a multi-channel research and development infrastructure in China. This infrastructure consists of 50 in-house researchers and engineers, a post-doctoral work center supported by the Chinese government, and collaborations with leading institutions and scientists.
Renhuang employs over 2,000 sales agents, and is establishing a strong sales network throughout China. The company has 70 sales centers that extend across 24 districts of China, and cover 50% of the greater China area, including the most populous and developed regions. Rehnuang also has begun to implement a leading marketing strategy focused on increased advertising, variable pricing to increased penetration in non-urban areas, sales centers in key cities such as Beijing and Shanghai and targeting top-tier medical facilities through high-quality products and GMP manufacturing processes.
Let us hear your thoughts below:
